Star Scientific Rises After Reporting Positive Results of Human Thyroid Study
Shares of small-cap name Star Scientific (NASDAQ: STSI) are higher on Tuesday after the company announced preliminary results of its Anatabloc Supplementation Autoimmune Prevention (ASAP) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health.
The company said that "Initial results for all study subjects suggest that dietary supplementation with anatabine ameliorates the immune system's targeting of the thyroid gland in autoimmune thyroiditis."
The press release also states that "The preliminary examination of the primary outcomes shows a clear and statistically significant difference in the treated group as compared to the placebo group by the end of the trial, with declines in anti-thyroglobulin antibody levels."
The stock gapped sharply higher at the open, but has since come off of its best levels of the day. At last check, STSI was trading up a little better than six percent to $2.91.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.